From Nasdaq.: 2024-08-02 07:19:00

The biotechnology industry struggled in the first half of 2024 due to high interest rates impacting revenue generation for many companies. However, a potential rate cut in September could turn things around for the industry, with a positive outlook for the second half.

Illumina Inc. (ILMN) is making strides in the gene-sequencing market, with growth in its oncology portfolio and positive earnings estimates. With an upcoming earnings report and strong market position, the company is poised for potential growth in the near future.

Genmab A/S (GMAB) specializes in antibody therapeutics for cancer treatment, with active pre-clinical programs and collaborations with various companies. The company has seen improvements in earnings estimates and is expected to report strong results in the upcoming quarter.

An upcoming report highlights a top stock pick with significant growth potential, targeting millennial and Gen Z audiences. This company has a strong revenue stream, making it an attractive investment opportunity in the current market.



Read more at Nasdaq.:: Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat